Spyre Therapeutics develops long-acting antibody therapies and antibody combinations for inflammatory bowel disease and rheumatic diseases. The company’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A and IL-23, with programs such as SPY001, SPY002 and SPY003 evaluated as monotherapies and pairwise combinations.
Recurring news for Spyre Therapeutics includes clinical updates from the SKYLINE platform trial in ulcerative colitis and the SKYWAY basket trial in rheumatic diseases, financial results and corporate updates, common-stock financing activity, and equity inducement awards under its 2018 Equity Inducement Plan. Company announcements also describe balance-sheet actions, development priorities and data presentations tied to its immune-mediated disease pipeline.
Spyre Therapeutics (NASDAQ: SYRE), a biotechnology company specializing in antibody engineering and precision medicine for Inflammatory Bowel Disease (IBD), will participate in the Jefferies Global Healthcare Conference. The event will feature a fireside chat and investor meetings on June 5, 2024, at 9:30 a.m. Eastern time. The webcast will be available on the Spyre website for 90 days post-conference.
Spyre Therapeutics (NASDAQ: SYRE) has appointed Dr. Sandra Milligan to its Board of Directors. Dr. Milligan, currently President of Aspira Women's Health, brings extensive experience in clinical development and regulatory affairs, particularly in Inflammatory Bowel Disease (IBD). Her expertise is expected to aid Spyre as they advance their antibody therapies targeting α4β7 and TL1A into clinical studies. Dr. Milligan will replace Russell Cox, whose term ended on May 13, 2024. Jeffrey Albers has been appointed Chairman of the Board in connection with Cox's departure.
Spyre Therapeutics, Inc. reported its first-quarter 2024 financial results and provided corporate updates. The company is advancing its anti-α4β7 antibody, SPY001, and anti-TL1A antibody, SPY002, towards first-in-human studies. With $485 million in cash and expected runway until 2027, Spyre is on track to achieve significant milestones in 2024 and beyond.
Spyre Therapeutics, Inc. announced the approval of grants of stock options to 4 non-executive employees as equity inducement awards. These options were granted under the 2018 Equity Inducement Plan with a 10-year term and an exercise price of $33.87 per share. The options will vest over time, subject to continuous service with Spyre.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.